tiprankstipranks
Allergy Therapeutics PLC (GB:AGY)
LSE:AGY

Allergy Therapeutics (AGY) Income Statement

4 Followers

Allergy Therapeutics Income Statement

Last quarter (Q4 2022), Allergy Therapeutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Allergy Therapeutics's net income was £―. See Allergy Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 23Jun 22Jun 21Jun 20Jun 19
Total Revenue
-£ 59.59M£ 72.77M£ 84.33M£ 78.20M£ 73.72M
Cost of Revenue
-£ 26.34M£ 23.26M£ 22.11M£ 20.20M£ 18.38M
Gross Profit
-£ 33.24M£ 49.51M£ 62.23M£ 58.00M£ 55.34M
Operating Expense
-£ 73.75M£ 62.49M£ 58.19M£ 49.69M£ 50.95M
Operating Income
-£ -40.51M£ -12.98M£ 4.03M£ 8.31M£ 4.39M
Net Non Operating Interest Income Expense
-£ -2.11M£ -412.00K£ 374.00K£ -238.00K£ -98.00K
Other Income Expense
-£ -856.00K£ -740.00K---
Pretax Income
-£ -41.77M£ -12.66M£ 3.66M£ 8.07M£ 4.29M
Tax Provision
-£ 1.30M£ 1.12M£ 771.00K£ 1.01M£ 826.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -43.07M£ -13.78M£ 2.89M£ 7.06M£ 3.47M
Basic EPS
-£ -0.06£ -0.02-£ 0.01£ <0.01
Diluted EPS
-£ -0.06£ -0.02-£ 0.01£ <0.01
Basic Average Shares
-£ 670.36M£ 642.99M£ 639.19M£ 636.17M£ 632.84M
Diluted Average Shares
-£ 670.36M£ 642.99M£ 676.66M£ 673.49M£ 669.70M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
----£ 0.00£ 2.35M
Total Expenses
-£ 100.10M£ 85.75M£ -80.30M£ 69.89M£ 69.33M
Net Income From Continuing And Discontinued Operation
-£ -43.07M£ -13.78M£ 2.89M£ 7.06M£ 3.47M
Normalized Income
-£ -33.83M£ -10.25M£ 2.96M£ 7.06M£ 3.47M
Interest Expense
----£ 504.00K£ 201.00K
EBIT
-£ -39.33M£ -11.99M£ 4.15M£ 8.57M£ 4.49M
EBITDA
-£ -35.10M£ -7.82M£ 4.15M£ 12.49M£ 6.58M
Currency in GBP

Allergy Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis